Renal considerations in patients with type 2 diabetesThis promotional module has been initiated, funded and reviewed soley by Boehringer Ingelheim. The content of this industry-supported learning activity has been generated by Practice Nurse. Links to prescribing information can be found at the foot of this page. INTRODUCTIONRenal impairment frequently co-exists with diabetes (type 1 and type 2).1 As many agents used to control blood glucose are metabolised by the kidneys, reduced renal function has important implications for the choice and dose of oral hypoglycaemic agents. This module aims to raise awareness of how chronic kidney disease (CKD) impacts on the management of hyperglycaemia, including the need for dose reduction for many agents used in the management of type 2 diabetes. LEARNING OBJECTIVESOn completion of this module, you will:
This module is one of a series of five. Others in the series are:
This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned. Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log. References 1. NICE NG203. Chronic kidney disease in adults: assessment and management, 2021. https://www.nice.org.uk/Guidance/ng203 [Accessed July 2022] Job Code: PC-GB-105039 Date of preparation: July 2022 You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events. Click here for Trajenta (linagliptin) Prescribing Information: Great Britain | Northern Ireland Click here for Jardiance (empagliflozin) Prescribing Information: Great Britain | Northern Ireland Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
|
|